A study indicates that longer Paxlovid treatments could improve long COVID symptoms in some patients, highlighting the need for tailored antiviral strategies.

VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Simaravibart is under clinical development by Contraria Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

It's hard to believe it's been five years since the start of COVID-19. This timeline serves as a reminder of those early days ...

This is the first time after 2001 that the virus has led to an outbreak, if any, in China. “It was first found in 2001 in an ...

A viral outbreak in China sounds alarmingly familiar to 2019, back in the days before most of us had ever heard of the ...

Merck & Co.’s Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat owners seize on them as ...

An Infectious Disease Specialist recalls what we have learned after Covid was first identified five years ago.

Another year has gone by since the 2020 pandemic and COVID-19 remains at large, so experts weigh in on what will change in 2025.

Covid has killed an estimated 20 million people globally, according to the World Health Organization, and thousands are still ...

Convenor of Alpha Hour, Pastor Elvis Agyemang, has dropped a prophecy about a pandemic in 2025. He gave a vivid description ...